--- title: "Bright Minds Biosciences (NASDAQ:DRUG) Cut to \"Sell\" at Wall Street Zen" type: "News" locale: "en" url: "https://longbridge.com/en/news/272143948.md" description: "Wall Street Zen downgraded Bright Minds Biosciences (NASDAQ:DRUG) from a \"hold\" to a \"sell\" rating. Despite this, several analysts maintain positive outlooks, with Cantor Fitzgerald reaffirming an \"overweight\" rating and BTIG Research raising the price target to $147. The stock has a consensus rating of \"Moderate Buy\" with an average target price of $115.40. Bright Minds focuses on developing therapeutics for mental health and neurodegenerative disorders, with its lead candidate in clinical development for mood and anxiety disorders." datetime: "2026-01-10T06:18:33.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/272143948.md) - [en](https://longbridge.com/en/news/272143948.md) - [zh-HK](https://longbridge.com/zh-HK/news/272143948.md) --- # Bright Minds Biosciences (NASDAQ:DRUG) Cut to "Sell" at Wall Street Zen Bright Minds Biosciences (NASDAQ:DRUG - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued on Saturday. - Biotechs on the Brink: 2 Stocks With Huge Potential Several other equities research analysts have also issued reports on DRUG. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Bright Minds Biosciences in a research note on Monday, December 1st. BTIG Research increased their price target on Bright Minds Biosciences from $72.00 to $147.00 and gave the company a "buy" rating in a report on Tuesday. Chardan Capital reaffirmed a "buy" rating and set a $80.00 price objective on shares of Bright Minds Biosciences in a research note on Friday, January 2nd. HC Wainwright reiterated a "buy" rating and set a $115.00 price objective on shares of Bright Minds Biosciences in a research report on Tuesday, December 30th. Finally, Robert W. Baird set a $142.00 target price on shares of Bright Minds Biosciences in a report on Wednesday. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, Bright Minds Biosciences currently has a consensus rating of "Moderate Buy" and an average target price of $115.40. **Check Out Our Latest Analysis on Bright Minds Biosciences** ## Bright Minds Biosciences Trading Down 3.6% - Bright Minds Biosciences Stock Surges Almost 1,500% DRUG opened at $86.75 on Friday. The firm has a market cap of $675.78 million, a P/E ratio of -71.11 and a beta of -6.15. Bright Minds Biosciences has a 12 month low of $23.17 and a 12 month high of $123.75. The stock has a 50-day moving average of $73.17 and a 200 day moving average of $53.59. ## Institutional Inflows and Outflows A number of hedge funds have recently made changes to their positions in the stock. Goldman Sachs Group Inc. bought a new stake in Bright Minds Biosciences during the 1st quarter valued at about $802,000. Sio Capital Management LLC grew its stake in Bright Minds Biosciences by 0.9% in the 2nd quarter. Sio Capital Management LLC now owns 512,338 shares of the company's stock worth $13,377,000 after acquiring an additional 4,776 shares in the last quarter. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Bright Minds Biosciences during the second quarter worth approximately $28,000. AdvisorShares Investments LLC increased its position in shares of Bright Minds Biosciences by 28.4% during the second quarter. AdvisorShares Investments LLC now owns 14,481 shares of the company's stock worth $378,000 after acquiring an additional 3,200 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in shares of Bright Minds Biosciences by 142.3% during the third quarter. JPMorgan Chase & Co. now owns 5,265 shares of the company's stock valued at $319,000 after acquiring an additional 3,092 shares in the last quarter. 40.52% of the stock is currently owned by institutional investors. ## Bright Minds Biosciences Company Profile (Get Free Report) Bright Minds Biosciences Inc, trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments. The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders. ## Further Reading - Five stocks we like better than Bright Minds Biosciences - Wall Street Stockpicker Names #1 Stock of 2026 - A U.S. “birthright” claim worth trillions - activated quietly - Do not delete, read immediately - How a Family Trust May Be Able To Help Preserve Your Wealth - Market Panic: Trump Just Dropped a Bomb on Your Stocks _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Bright Minds Biosciences Right Now? Before you consider Bright Minds Biosciences, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bright Minds Biosciences wasn't on the list. While Bright Minds Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [DRUG.US](https://longbridge.com/en/quote/DRUG.US.md) ## Related News & Research - [‘Solve all diseases,’ you say?](https://longbridge.com/en/news/287121830.md) - [BioMarin drug acquired in buyout misses goal in rare disease study](https://longbridge.com/en/news/287075291.md) - [VMD Sciences Expands Veterinary Pharmaceutical Supply Solutions to Address Drug Shortages and Emerging Disease Threats in the United States](https://longbridge.com/en/news/287125444.md) - [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md) - [BioMarin's drug shows significant growth gains in children in late-stage trial](https://longbridge.com/en/news/287121584.md)